Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Hold" by Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has earned a consensus recommendation of "Hold" from the ten research firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.50.

PCRX has been the subject of a number of analyst reports. Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research report on Tuesday, November 12th. Jefferies Financial Group upped their target price on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a research report on Tuesday, September 24th. Royal Bank of Canada lifted their price target on shares of Pacira BioSciences from $15.00 to $16.00 and gave the company a "sector perform" rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a "buy" rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Pacira BioSciences in a research note on Friday, November 8th.

Pacira BioSciences Stock Up 1.4 %

Shares of PCRX stock traded up $0.27 on Wednesday, hitting $19.47. The company's stock had a trading volume of 269,949 shares, compared to its average volume of 856,936. The stock has a market capitalization of $898.99 million, a price-to-earnings ratio of -9.59 and a beta of 0.80. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $35.95. The firm's fifty day moving average price is $17.76 and its 200-day moving average price is $18.45. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Institutional Investors Weigh In On Pacira BioSciences

Several hedge funds have recently made changes to their positions in the stock. Innealta Capital LLC acquired a new position in Pacira BioSciences in the 2nd quarter valued at approximately $50,000. nVerses Capital LLC raised its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock valued at $51,000 after purchasing an additional 1,600 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Pacira BioSciences in the second quarter valued at $113,000. Canada Pension Plan Investment Board bought a new position in Pacira BioSciences in the second quarter worth $140,000. Finally, Virtus Investment Advisers Inc. acquired a new stake in Pacira BioSciences during the third quarter worth $98,000. Institutional investors own 99.73% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.